Clinical trial

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-03-05

PhasePHASE1

Study timeline

Study start (actual)2025-03-05Date precision: day

Registry last updated2026-06-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cancerunresolved

PDAC - Pancreatic Ductal Adenocarcinomaunresolved

NSCLC (Non-small Cell Lung Cancer)unresolved

CRC (Colorectal Cancer)unresolved

Advanced Solid Tumorsunresolved

Interventions

cetuximabDRUG · verified · RxNorm: cetuximab

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Pemetrexed + Cisplatin /CarboplatinDRUG

mFOLFIRINOXDRUG

GnPDRUG

MidazolamDRUG · verified · RxNorm: midazolam

Sponsors & collaborators

Alterome Therapeutics, Inc.lead sponsor

Mapped research locations

New YorkNew York, United States2 BostonMassachusetts, United States2 San AntonioTexas, United States2 HoustonTexas, United States1 St LouisMissouri, United States1 NashvilleTennessee, United States1 DurhamNorth Carolina, United States1 OrlandoFlorida, United States1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06835569 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.